Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by AstraZeneca
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01144338
First received: June 10, 2010
Last updated: August 12, 2015
Last verified: August 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: April 2018
  Estimated Primary Completion Date: April 2018 (Final data collection date for primary outcome measure)
No publications provided by AstraZeneca

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):